$4.06
-0.24 (-5.58%)
Open$4.24
Previous Close$4.30
Day High$4.37
Day Low$4.01
52W High$13.50
52W Low$3.25
Volume—
Avg Volume176.5K
Market Cap61.12M
P/E Ratio—
EPS$-3.49
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+364.5% upside
Current
$4.06
$4.06
Target
$18.86
$18.86
$15.04
$18.86 avg
$28.67
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 288.5K | 383.6K | 28.89M |
| Net Income | -37,735,277 | -45,149,892 | 2.55M |
| Profit Margin | -13,086.5% | -12,432.2% | 8.8% |
| EBITDA | -31,124,355 | -39,308,876 | 4.88M |
| Free Cash Flow | — | — | 2.44M |
| Rev Growth | -24.8% | -24.8% | +0.1% |
| Debt/Equity | 1.99 | 1.99 | 0.72 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |